Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

NCT05620628 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Stomach Cancer, Adenocarcinoma

Interventions

DRUG: Durvalumab
DRUG: Savolitinib

Sponsor

Jeeyun Lee